Management of Hepatitis C Infection
Summary
- Ledipasvir/sofosbuvir is approved by the FDA for treatment of genotypes 1, 4, 5, and 6 HCV[FDA Ledipasvir/Sofosbuvir] and by the EMA for treatment of genotypes 1, 3, 4, 5, and 6 HCV infection in adults and adolescents 12 years of age or older[EMA Ledipasvir/Sofosbuvir]
- Ledipasvir/sofosbuvir approved as stand-alone peginterferon- and ribavirin-free therapy in the United States and in some populations in Europe
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Hepatitis C-Treatment